Alnylam's Amvuttra Hit $1 Billion in a Quarter. The Stock Still Fell.

Alnylam's Amvuttra just crossed $1 billion in a single quarter for the first time. The stock fell 29%.

That is how you know the narrative has outrun the numbers.

On July 30, Alnylam reported Q2 2026 revenue of $1.29 billion with TTR franchise revenue — dominated by Amvuttra — hitting $1.03 billion, up 89% from a year ago. Amvuttra alone brought in $1.01 billion in net product revenue. The earnings beat estimates. Non-GAAP operating income tripled to $318 million. The company holds $3.3 billion in cash and marketable securities.

Investors sold anyway. Management lowered full-year 2026 combined net product revenue guidance to $4.7–$5.1 billion (midpoint $4.9 billion) from $4.9–$5.3 billion (midpoint $5.1 billion). TTR-specific guidance dropped from $4.4–$4.7 billion to $4.2–$4.5 billion. A $200 million reduction at the midpoint.

The stock dropped 25% in premarket trading, falling from around $286 to $214, near its 52-week low.

Here's what the market heard: Amvuttra growth is slowing. The thesis is breaking.

Here's what actually happened: the second-line pent-up demand that fueled the initial launch surge has normalized. That was always going to happen. First-line new patient starts now account for roughly 80% of category growth — and first-line prescribing is the sustainable growth engine, not a one-time rush of switching patients.

This is the difference between growing pains and a structural problem. Alnylam is living through the former while the market priced it as the latter.

The launch curve tells the real story

Amvuttra was approved for ATTR-CM in early 2025. The first commercial quarter generated $490 million. By Q1 2026, total TTR revenue hit $910 million — up 153% year-over-year. Q2 2026 brought $1.03 billion in TTR revenue — up 13% sequentially.

That trajectory is what a drug looks like at the inflection point from launch to growth. You don't slow that kind of momentum because the business model is broken. You slow it because you're moving from the chaotic early adoption phase — where every delayed diagnosis catches up at once — to the predictable steady state of a growing market.

Management called it exactly what it was: normalization of second-line demand growth in the U.S. ATTR-CM market after an initial period of pent-up demand. Patients who had been on tafamidis for years and were finally switching to Amvuttra are no longer a source of new quarterly demand. The next growth comes from first-line prescriptions — patients starting Amvuttra as their initial treatment — and that's happening at 80% of all category growth now.

There is nothing wrong with that. It's the opposite.

The category itself is still opening

ATTR-CM is a rare disease — misdiagnosed, underdiagnosed, and historically treated with tafamidis, a TTR stabilizer that slows progression but doesn't silence the protein. Amvuttra (vutrisiran) is the first and only TTR-silencing therapy approved for ATTR-CM, and the clinical evidence keeps widening the addressable population.

The HELIOS-B Phase 3 trial met all 10 of its endpoints. Over 48 months, Amvuttra reduced all-cause mortality and recurrent cardiovascular events by nearly 40% compared to placebo. But the subgroup data is where the commercial thesis strengthens.

The treatment effect was preserved across every major patient category — patients with atrial fibrillation (about 65% of the ATTR-CM population), patients with low systolic blood pressure, patients already on TTR stabilizers, and patients with declining kidney function. In patients on background stabilizer therapy, Amvuttra provided an additional 41% reduction in all-cause mortality risk. The benefit was most pronounced in early-stage patients: those with lower BNP levels saw a 47% reduction in the composite endpoint; patients with better walking ability saw 42%; younger patients, 45%.

What this means commercially is that the drug works regardless of where a patient is in the disease — from first diagnosis through advanced stages and across combinations with existing therapies. That removes prescription barriers. A cardiologist doesn't need to wait for a patient to fail on tafamidis before considering Amvuttra. The data supports it as a first-line option.

Then there's the screening push. Alnylam collaborated with a major California healthcare system on DETECT-ATTR, an AI-enabled echocardiography screening program to detect cardiac amyloidosis. The DemonsTTRate study — a global, prospective, observational study of over 2,000 ATTR-CM patients across five years — is building the real-world evidence that turns rare-disease awareness into routine clinical pathways.

Early detection drives first-line starts. First-line starts drive predictable revenue. The flywheel is turning, even if the market read the guidance cut as a broken gear.

The valuation doesn't price in the trajectory

Alnylam's market cap sits at $31.7 billion, down from a 52-week high near $495 per share to around $237 today. That's a 40% decline year-to-date.

The trailing P/E is about 41x — ugly on its own — but the forward P/E is negative because analysts are modeling near-term investment drag from the ZENITH Phase 3 trial and pipeline expansion. The forward multiple is a broken measurement here, not a signal of value destruction. The revenue growth rate tells a different story.

Q2 2026 total net product revenue was $1.17 billion, up 74% from the prior year. Q1 was up 121%. Annualized from the Q2 run-rate, that's roughly $4.7 billion — right at the midpoint of the lowered guidance. The company is on track for the revised target from the current trajectory.

At the midpoint of lowered guidance ($4.9 billion), the stock trades at about 6.5x 2026 net product revenue. That's not a cheap multiple for a company growing revenue at 70%+ and entering the second year of a blockbuster drug's commercial life. But it's not a 52-week-high multiple either. The drop from panic has moved Alnylam from expensive-growth to reasonable-growth territory.

The PEG ratio shows 0.11 — a number that would normally signal extreme undervaluation, though it's noisy given the forward earnings distortion. The more useful comparison is against the revenue growth embedded in the model: at roughly 6.5x projected sales for a company that just crossed $1 billion per quarter on a single drug, the market is pricing in that the growth stops.

The math says it doesn't have to.

The second act: hypertension

None of this is priced in the $31.7 billion market cap: the hypertension pipeline.

Zilebesiran targets angiotensinogen — the upstream precursor in the renin-angiotensin-aldosterone system — with biannual subcutaneous dosing. It's co-developed with Roche, and the $300 million milestone payment was triggered when the Phase 3 ZENITH trial started its first patient dose in October 2025.

ZENITH will enroll approximately 11,000 patients across 35 countries to assess cardiovascular outcomes — CV death, nonfatal heart attack, nonfatal stroke, or heart failure events — in patients with uncontrolled hypertension and established or high-risk cardiovascular disease.

Hypertension affects over 160 million Americans. The global anti-hypertensive drugs market is projected to reach $30.7 billion by 2030. This is not a niche program. This is the kind of addressable market that defines company value.

The Phase 2 KARDIA-3 data showed a placebo-adjusted reduction of 5.0 mmHg in systolic blood pressure at the 300 mg dose, sustained through six months. In patients with baseline systolic ≥140 mmHg on a diuretic plus other antihypertensives, the reduction was 8.3 mmHg at six months. The safety profile was clean: serious adverse events at 3.8% versus 4.5% for placebo, no deaths during the double-blind period.

The Phase 3 data isn't here yet. That's the risk. But the pipeline is actively advancing, Roche is sharing development and commercial costs, and Roche collaboration revenue in Q2 2026 rose 129% to $41.9 million driven by ZENITH activities. The infrastructure is being built now for a program that could reclassify Alnylam from a rare-disease company to a cardiovascular powerhouse.

The pipeline depth most investors aren't tracking

Nucresiran — a next-generation TTR silencer with a projected >95% knockdown, deeper and less variable than vutrisiran's ~87% — is in Phase 3 for ATTR-CM and hATTR-PN under the TRITON-CM trial. AstraZeneca's eplontersen failed its CARDIO-TTRansform study, leaving Alnylam with one fewer branded competitor and a clear path for nucresiran as a potential second-generation TTR therapy.

Beyond that: mivelsiran in Alzheimer's disease (Phase 2 for Down syndrome-associated Alzheimer's, Phase 1 data showing robust amyloid reduction with no ARIA signal), ALN-6400 for von Willebrand disease (Phase 2 initiated), and ALN-6222 for obesity (Phase 1 initiated). RNAi as a platform is Alnylam's moat, and each new target validated adds optionality that a single-drug revenue narrative doesn't capture.

Where the math lands

The question for an investor isn't whether Amvuttra is a great drug. The data says it is. The question is whether Alnylam is a $31.7 billion company or a $50 billion one.

At the midpoint of the lowered guidance — $4.9 billion in 2026 net product revenue — the stock trades at roughly 6.5x sales. If first-line starts continue driving 80% of category growth and ATTR-CM awareness keeps expanding, 2027 could reasonably push toward $6 billion in combined net product revenue. That would compress the multiple to under 5x forward sales.

That's the disconnect. A company with 70%+ revenue growth, $3.3 billion in cash, a $1 billion-per-quarter drug, an 11,000-patient Phase 3 cardiovascular outcomes trial in a $30 billion market, and a pipeline stretching from Alzheimer's to obesity — trading at the multiple you'd give a business in deceleration.

The stock won't recover because Amvuttra is a good drug. It'll recover because the market is pricing the normalization of launch dynamics as a growth ceiling, and the math doesn't support that ceiling.

The break condition is the next earnings report. If Q3 2026 revenue holds the Q2 trajectory — around $1.17–$1.3 billion in net product revenue — the normalization story confirms itself as a one-time adjustment, not a structural shift. If first-line starts keep growing at the stated pace, the growth argument strengthens regardless of what the headline multiple says today.

If anything breaks — nucresiran enrollment stalls, ZENITH under-enrolls, or first-line adoption slows — the thesis needs reassessing. Those are the real risks, not the guidance cut from July.